Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 ...

Biocon Biologics Ltd., today announced the Company has secured multiple market access agreements for Yesintek™ ...

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara ...

Biocon Biologics secures market access agreements for Yesintek, a biosimilar to Stelara, for treating autoimmune diseases in ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced the Company has secured multiple market access ...

Biocon Biologics secures market access for Yesintek in the US driven by demand from national and commercial formularies: Our Bureau, Bengaluru Monday, May 5, 2025, 12:15 Hrs [IST] ...

Biocon advanced 3.17% to Rs 328.75 after Biocon Biologics (BBL) secures multiple market access agreements in the United States for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab), ...

Biocon Biologics secures multiple market access agreements in the US for its biosimilar, Yesintek, for treating Crohn's ...

The drug has been chosen as the sole ustekinumab by BCBSM, Florida Healthcare Plan, and other closed-door health systems.

The Rite Aid closings could create pharmacy deserts in small communities like Eden and Silver Creek, which would be without a ...

While the proposal was nixed, Jordan wanted to use a spending bill to gut the Federal Trade Commission and its ability to ...